Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Phase 2
Completed
- Conditions
- Lymphoma
- Interventions
- Biological: filgrastimBiological: pegfilgrastimBiological: rituximabDrug: cyclophosphamideDrug: prednisoneDrug: liposome-encapsulated doxorubicin citrateDrug: vincristine sulfate
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 67
- Registration Number
- NCT00911183
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia
Withdrawn
- Conditions
- Acute Lymphoblastic LeukemiaUntreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: Daunorubicin HydrochlorideOther: Pharmacological StudyDrug: PrednisoloneDrug: PrednisoneDrug: Vincristine Sulfate
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Children's Oncology Group
- Registration Number
- NCT00900445
- Locations
- 🇺🇸
Childrens Oncology Group, Philadelphia, Pennsylvania, United States
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
Phase 2
- Conditions
- Lymphoma
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 30
- Registration Number
- NCT00896519
The Use of Oral Steroids in the Treatment of Cellulitis
Phase 2
Withdrawn
- Conditions
- CellulitisErysipelas
- Interventions
- Drug: Placebo Oral TabletDrug: Prednisone
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Milton S. Hershey Medical Center
- Registration Number
- NCT00893048
Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis
Phase 1
Completed
- Conditions
- Lung CancerMetastatic Cancer
- Interventions
- Procedure: Cryotherapy (PTC)Drug: Prednisone
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT00890617
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 3
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1088
- Registration Number
- NCT00887198
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Phase 2
Terminated
- Conditions
- LeukemiaLymphoma
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00882206
- Locations
- 🇺🇸
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
Phase 1
Terminated
- Conditions
- Stage IV Prostate CancerProstate CancerStage III Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate Cancer
- Interventions
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- John P. Fruehauf
- Target Recruit Count
- 4
- Registration Number
- NCT00879619
- Locations
- 🇺🇸
Chao Comprehensive Cancer Center, Orange, California, United States
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Phase 3
Completed
- Conditions
- Non-Hodgkin's LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT00877006
- Locations
- 🇺🇸
Teva Investigational Site 52, Fountain Valley, California, United States
🇺🇸Teva Investigational Site 72, Augusta, Georgia, United States
🇺🇸Teva Investigational Site 48, Chicago, Illinois, United States
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2
Completed
- Conditions
- B-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Lymphoblastic Lymphoma
- Interventions
- Drug: L-asparaginaseDrug: doxorubicin hydrochlorideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateDrug: cytarabineDrug: prednisoneDrug: bortezomibDrug: pegaspargaseDrug: methotrexateDrug: etoposide phosphateDrug: cyclophosphamideBiological: filgrastimDrug: leucovorin calciumOther: laboratory biomarker analysisDrug: High Dose MTX
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00873093
- Locations
- 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath